Evidence map›Paper›PMID 38859776›Full record

ReviewCurrent topics in medicinal chemistry2024

A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.

Vishal Chavda, Dhananjay Yadav, Harisinh Parmar, Raxit Brahmbhatt, Bipin Patel, Kajal Madhwani, Meenu Jain, Minseok Song, Snehal Patel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vishal ChavdaDepartment of Pathology, Stanford School of Medicine, Stanford University Medical Center, Palo Alto94305, CA, USA.
Dhananjay YadavDepartment of Life Science, Yeungnam University, South Korea.
Harisinh ParmarDepartment of Neurosurgery, Krishna institute of medical sciences, Karad, Maharashtra, India.
Raxit BrahmbhattDepartment of Medicine, Multispeciality, Trauma and ICCU Center, Sardar Hospital, Ahmedabad, 382352, Gujarat, India.
Bipin PatelDepartment of Medicine, Multispeciality, Trauma and ICCU Center, Sardar Hospital, Ahmedabad, 382352, Gujarat, India.
Kajal MadhwaniDepartment of Life Science, University of Westminster, London, W1B 2HW, United Kingdom.
Meenu JainGajra Raja Medical College, Gwalior, 474009, Madhya Pradesh, India.
Minseok SongDepartment of Life Science, Yeungnam University, South Korea.
Snehal PatelDepartment of Pharmacology, Nirma University, Ahmedabad, 382481, Gujarat, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global pandemic known as coronavirus disease (COVID-19) is causing morbidity and mortality on a daily basis. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV- -2) virus has been around since December 2019 and has infected a high number of patients due to its idiopathic pathophysiology and rapid transmission. COVID-19 is now deemed a newly identified "syndrome" condition since it causes a variety of unpleasant symptoms and systemic side effects following the pandemic. Simultaneously, it always becomes potentially hazardous when new variants develop during evolution. Its random viral etiology prevents accurate and suitable therapy. Despite the fact that multiple preclinical and research studies have been conducted to combat this lethal virus, and various therapeutic targets have been identified, the precise course of therapy remains uncertain. However, just a few drugs have shown efficacy in treating this viral infection in its early stages. Currently, several medicines and vaccinations have been licensed following clinical trial research, and many countries are competing to find the most potent and effective immunizations against this highly transmissible illness. For this narrative review, we used PubMed, Google Scholar, and Scopus to obtain epidemiological data, pre-clinical and clinical trial outcomes, and recent therapeutic alternatives for treating COVID-19 viral infection. In this study, we discussed the disease's origin, etiology, transmission, current advances in clinical diagnostic technologies, different new therapeutic targets, pathophysiology, and future therapy options for this devastating virus. Finally, this review delves further into the hype surrounding the SARS-CoV-2 illness, as well as present and potential COVID-19 therapies.

Indexed as

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentSARS-CoV-2Virus InternalizationCOVID-19 VaccinesHumansVirus ReplicationAntiviral AgentsCOVID-19 Vaccinesand Vaccine resistance.Coronavirus-2COVID-19ImmunizationRemdesivirSARS-CoV variationsSevere acute respiratory illnessViral infection

Identifiers

PMID38859776

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.